期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 31, 期 8, 页码 687-708出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543776.2021.1903431
关键词
Decoglurant; metabotropic glutamate receptor subtype 2; metabotropic glutamate receptor subtype 3; negative allosteric modulator; Alzheimer’ s disease; anxiety; cognition; depression
资金
- University of North Texas Health Science Center
Group II metabotropic glutamate (mGlu) receptors are promising targets for novel CNS therapeutics. This review summarizes patent applications for small molecule negative allosteric modulators (NAMs) targeting mGlu receptors between January 2015 and November 2020. Progress has been made in the discovery of new mGlu(2) NAMs, while mGlu(3) NAMs are more limited but show promise.
Introduction Group II metabotropic glutamate (mGlu) receptors have emerged as an attractive potential target for the development of novel CNS therapeutics in areas such as Alzheimer's disease (AD), anxiety, cognitive disorders, depression, and others. Several small molecules that act as negative allosteric modulators (NAMs) on these receptors have demonstrated efficacy and/or target engagement in animal models, and one molecule (decoglurant) has been advanced into clinical trials. Areas covered This review summarizes patent applications published between January 2015 and November 2020. It is divided into three sections: (1) small molecule nonselective mGlu(2/3) NAMs, (2) small molecule selective mGlu(2) NAMs, and (3) small molecule selective mGlu(3) NAMs. Expert Opinion Much progress has been made in the discovery of novel small molecule mGlu(2) NAMs. Still, chemical diversity remains somewhat limited and room for expansion remains. Progress with mGlu(3) NAMs has been more limited; however, some promising molecules have been disclosed. The process of elucidating the precise role of each receptor in the diseases associated with group II receptors has begun. Continued studies in animals with selective NAMs for both receptors will be critical in the coming years to inform researchers on the right compound profile and patient population for clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据